Endeavour Silver posts Q3 silver equivalent production of 3.6 million oz
Bitget2026/10/08 10:50Endeavour Silver reported Q3 2026 production of 2,096,545 oz silver, up 19%, with 10,126 oz gold, up 39%. Silver-equivalent output rose 19% to 3,611,034 oz; sales totaled 1,900,368 oz silver, up 8%, with 9,499 oz gold, up 27%. Year-to-date silver production reached 5,915,874 oz, up 33%; gold totaled 32,340 oz, up 38%; silver-equivalent rose 40% to 10,390,771 oz. Terronera was suspended Aug. 12-24, trimming throughput to 165,171 tonnes from 175,729; it produced 710,670 oz silver, 7,157 oz gold. Full-year production and cost guidance is being recalculated; output expected at or slightly below the low end of the range. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endeavour Silver Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080650PRIMZONEFULLFEED9841886) on October 08, 2026, and is solely responsible for the information contained therein.
- Endeavour Silver reported Q3 2026 production of 2,096,545 oz silver, up 19%, with 10,126 oz gold, up 39%.
- Silver-equivalent output rose 19% to 3,611,034 oz; sales totaled 1,900,368 oz silver, up 8%, with 9,499 oz gold, up 27%.
- Year-to-date silver production reached 5,915,874 oz, up 33%; gold totaled 32,340 oz, up 38%; silver-equivalent rose 40% to 10,390,771 oz.
- Terronera was suspended Aug. 12-24, trimming throughput to 165,171 tonnes from 175,729; it produced 710,670 oz silver, 7,157 oz gold.
- Full-year production and cost guidance is being recalculated; output expected at or slightly below the low end of the range.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
